Benedikt Schrage1,2, Alicia Uijl1,3, Lina Benson1, Dirk Westermann2, Marcus Ståhlberg1, Davide Stolfo1,4, Ulf Dahlström5, Cecilia Linde1, Frieder Braunschweig1, Gianluigi Savarese1. 1. Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden (B.S., A.U., L.B., M.S., D.S., C.L., F.B., G.S.). 2. University Heart Centre Hamburg, Department of General and Interventional Cardiology and German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Lübeck/Kiel (B.S., D.W.). 3. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, The Netherlands (A.U.). 4. Division of Cardiology, Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste, Italy (D.S.). 5. Department of Cardiology and Department of Medical and Health Sciences, Linköping University, Sweden (U.D.).
Abstract
BACKGROUND: Most randomized trials on implantable cardioverter-defibrillator (ICD) use for primary prevention of sudden cardiac death in heart failure with reduced ejection fraction enrolled patients >20 years ago. We investigated the association between ICD use and all-cause mortality in a contemporary heart failure with reduced ejection fraction cohort and examined relevant subgroups. METHODS: Patients from the Swedish Heart Failure Registry fulfilling the European Society of Cardiology criteria for primary-prevention ICD were included. The association between ICD use and 1-year and 5-year all-cause and cardiovascular (CV) mortality was assessed by Cox regression models in a 1:1 propensity score-matched cohort and in prespecified subgroups. RESULTS: Of 16 702 eligible patients, only 1599 (10%) had an ICD. After matching, 1305 ICD recipients were compared with 1305 nonrecipients. ICD use was associated with a reduction in all-cause mortality risk within 1 year (hazard ratio, 0.73 [95% CI, 0.60-0.90]) and 5 years (hazard ratio, 0.88 [95% CI, 0.78-0.99]). Results were consistent in all subgroups including patients with versus without ischemic heart disease, men versus women, those aged <75 versus ≥75 years, those with earlier versus later enrollment in the Swedish heart failure registry, and patients with versus without cardiac resynchronization therapy. CONCLUSIONS: In a contemporary heart failure with reduced ejection fraction population, ICD for primary prevention was underused, although it was associated with reduced short- and long-term all-cause mortality. This association was consistent across all the investigated subgroups. These results call for better implementation of ICD therapy.
BACKGROUND: Most randomized trials on implantable cardioverter-defibrillator (ICD) use for primary prevention of sudden cardiac death in heart failure with reduced ejection fraction enrolled patients >20 years ago. We investigated the association between ICD use and all-cause mortality in a contemporary heart failure with reduced ejection fraction cohort and examined relevant subgroups. METHODS:Patients from the Swedish Heart Failure Registry fulfilling the European Society of Cardiology criteria for primary-prevention ICD were included. The association between ICD use and 1-year and 5-year all-cause and cardiovascular (CV) mortality was assessed by Cox regression models in a 1:1 propensity score-matched cohort and in prespecified subgroups. RESULTS: Of 16 702 eligible patients, only 1599 (10%) had an ICD. After matching, 1305 ICD recipients were compared with 1305 nonrecipients. ICD use was associated with a reduction in all-cause mortality risk within 1 year (hazard ratio, 0.73 [95% CI, 0.60-0.90]) and 5 years (hazard ratio, 0.88 [95% CI, 0.78-0.99]). Results were consistent in all subgroups including patients with versus without ischemic heart disease, men versus women, those aged <75 versus ≥75 years, those with earlier versus later enrollment in the Swedish heart failure registry, and patients with versus without cardiac resynchronization therapy. CONCLUSIONS: In a contemporary heart failure with reduced ejection fraction population, ICD for primary prevention was underused, although it was associated with reduced short- and long-term all-cause mortality. This association was consistent across all the investigated subgroups. These results call for better implementation of ICD therapy.
Authors: Orison O Woolcott; Kyndaron Reinier; Audrey Uy-Evanado; Gregory A Nichols; Eric C Stecker; Jonathan Jui; Sumeet S Chugh Journal: Heart Rhythm Date: 2020-06-04 Impact factor: 6.343
Authors: Victor Nauffal; Peter Marstrand; Larry Han; Victoria N Parikh; Adam S Helms; Jodie Ingles; Daniel Jacoby; Neal K Lakdawala; Sunil Kapur; Michelle Michels; Anjali T Owens; Euan A Ashley; Alexandre C Pereira; Joseph W Rossano; Sara Saberi; Christopher Semsarian; James S Ware; Samuel G Wittekind; Sharlene Day; Iacopo Olivotto; Carolyn Y Ho Journal: Eur Heart J Date: 2021-10-07 Impact factor: 35.855
Authors: D A Theuns; T E Verstraelen; A C J van der Lingen; P P Delnoy; C P Allaart; L van Erven; A H Maass; K Vernooy; A A M Wilde; E Boersma; J G Meeder Journal: Neth Heart J Date: 2022-09-06 Impact factor: 2.854
Authors: Kieran F Docherty; Pardeep S Jhund; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; David L DeMets; Marc S Sabatine; Olof Bengtsson; Mikaela Sjöstrand; Anna Maria Langkilde; Akshay S Desai; Mirta Diez; Jonathan G Howlett; Tzvetana Katova; Charlotta E A Ljungman; Eileen O'Meara; Mark C Petrie; Morten Schou; Subodh Verma; Pham Nguyen Vinh; Scott D Solomon; John J V McMurray Journal: Eur Heart J Date: 2020-07-01 Impact factor: 29.983
Authors: Francisco Gama; Jorge Ferreira; João Carmo; Francisco Moscoso Costa; Salomé Carvalho; Pedro Carmo; Diogo Cavaco; Francisco Belo Morgado; Pedro Adragão; Miguel Mendes Journal: J Am Heart Assoc Date: 2020-04-15 Impact factor: 5.501